On June 22, 2026, four insiders at Kymera Therapeutics, Inc. (KYMR) executed a series of sales, divesting a combined total of approximately $24.89 million in company stock. Bruce Booth, an insider at the company, was notably active, selling a substantial number of shares across multiple transactions.
The sales by Booth included 92,169 shares at an average price of $90.38 per share, totaling $8.33 million. Additional transactions by Booth saw him sell 62,897 shares at $90.48 ($5.69 million), 56,348 shares at $100.17 ($5.64 million), and 52,442 shares at $99.57 ($5.22 million).
While insider selling can be attributed to various personal financial decisions such as diversification or tax planning, the coordinated nature of these sales by multiple individuals may draw investor attention. Kymera Therapeutics, Inc. operates in the biotechnology sector, focusing on targeted protein degradation therapies.